
Mission Therapeutics appoints new chief medical officer
pharmafile | September 9, 2015 | Appointment | Medical Communications, Research and Development | Dr Michael Koslowski, Mission Therapeutics
Mission Therapeutics has announced the appointment of Dr Michael Koslowski as chief medical officer.
Dr Koslowski brings over 15 years’ experience across biopharmaceutical research and development, specialising in drug target discovery and clinical validation.
He joins Mission from Glenmark Pharmaceuticals where he served as head of clinical sciences and early development and led Glenmark’s first oncology development programme.
Dr Koslowski says: “Mission has developed a proprietary and world-class technological and transferable expertise in developing DUB inhibitors. I am thrilled to join this highly experienced team in progressing the potential of the Company’s platform.”
Prior to this, Dr Koslowski was global head of translational medicine experts at Boehringer Ingelheim, where he had oversight of the transition of projects and programmes across all therapeutic areas, from early research through to clinical proof of concept.
Previous to Boehringer Ingelheim, Dr Koslowski was associate professor of molecular medicine at the University of Mainz. He is also a founding member and former group head.
Dr Anker Lundemose, chief executive of Mission Therapeutics, says: “We are very pleased to welcome Dr Koslowski to Mission’s senior management team. His track record and expertise in successfully translating research into the clinic will enable us to further advance our proprietary DUB platform, and develop new classes of medicines in cancer as well as other disease areas with high unmet medical need.
“This appointment supports Mission’s growth strategy as we continue to transition our business into a clinical stage organisation. We look forward to benefiting from Dr Koslowski’s experience and in-depth knowledge of clinical development.”
Related Content

FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its …






